Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 7:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 76 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Moxifloxacin Matching Placebo Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Effect of Estetrol Monohydrate (E4) on QTc Interval

NCT04819906
View directory record Official record
Conditions
Prolonged QTc Interval
Interventions
Estetrol 20 mg, Estetrol 100 mg, Placebo, Moxifloxacin 400 mg
Drug
Lead sponsor
Estetra
Industry
Eligibility
40 Years to 65 Years · Female only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effect of WCK 5222 on the QT/QTc Interval in Healthy Volunteers

NCT03554304
View directory record Official record
Conditions
QT/QTc Interval in Healthy Volunteers
Interventions
WCK 5222, IV placebo matched to WCK 5222 / Moxifloxacin IV solution, Moxifloxacin 400-mg
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Investigate the Effects of CBP-307 on the Heart Rate-corrected QT Interval (QTc) in Healthy Subjects

NCT04818229
View directory record Official record
Conditions
Autoimmune Diseases
Interventions
CBP-307, Placebo-matched CBP-307, Moxifloxacin (Avelox), Placebo-matched Moxifloxacin
Drug
Lead sponsor
Connect Biopharma Australia Pty Ltd
Industry
Eligibility
18 Years to 60 Years
Enrollment
112 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Hialeah, Florida
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

NCT07272629
View directory record Official record
Conditions
Cardiac Repolarization, Healthy Volunteers
Interventions
Balinatunfib, Moxifloxacin, Placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of BL-8040 (Motixafortide) on the QTc Interval in Healthy Subjects

NCT05293171
View directory record Official record
Conditions
Healthy Subjects
Interventions
1.25 mg/kg BL-8040 + BL-8040-matching placebo, 2 mg/kg BL-8040, BL-8040-matching placebo, 400 mg Moxifloxacin (1x400 mg tablet)
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 21, 2025 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

The Effect of Buprenorphine Delivered by Buprenorphine Transdermal System (BTDS) on QT Intervals in Healthy Volunteers

NCT01148537
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Buprenorphine transdermal patch, Matching placebo transdermal patch, Avelox (moxifloxacin hydrochloride) tablet
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 55 Years
Enrollment
132 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2012 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Hydrocodone Bitartrate (HYD) Extended-Release Tablets on QT /QTc Intervals in Healthy Adult Subjects

NCT02243241
View directory record Official record
Conditions
Healthy
Interventions
HYD, Moxifloxacin, Placebo for HYD, Placebo for moxifloxacin
Drug
Lead sponsor
Purdue Pharma LP
Industry
Eligibility
18 Years to 50 Years
Enrollment
208 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Thorough QT Study of Telotristat Etiprate

NCT02155205
View directory record Official record
Conditions
QT Interval
Interventions
Telotristat etiprate, Placebo, Moxifloxacin
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Evansville, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants

NCT05046132
View directory record Official record
Conditions
Healthy
Interventions
Setmelanotide, Moxifloxacin, Oral Placebo, SC Placebo
Drug
Lead sponsor
Rhythm Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 3, 2024 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of Electrocardiogram (ECG) Effects of Sancuso® (Granisetron TDS)

NCT00890565
View directory record Official record
Conditions
Healthy
Interventions
granisetron
Drug
Lead sponsor
Kyowa Kirin Co., Ltd.
Industry
Eligibility
18 Years to 50 Years
Enrollment
240 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 17, 2024 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate the Effects of Tramadol Hydrochloride on Cardiac Repolarization in Healthy Participants

NCT02307864
View directory record Official record
Conditions
Healthy
Interventions
Tramadol HCl, Moxifloxacin 400 mg, Tramadol HCl Placebo, Moxifloxacin Placebo
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
68 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 29, 2018 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Electrocardiogram Study to Evaluate the Effect of Vanzacaftor on the QT/QTc Interval in Healthy Participants

NCT05867147
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Vanzacaftor, Vanzacaftor Placebo, Moxifloxacin, Moxifloxacin Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Jul 14, 2023 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of JNJ-64565111 on Cardiac Repolarization (Corrected QT Interval) Compared With Placebo in Healthy Adults: a Thorough ECG Study Employing Placebo, JNJ-64565111, and a Positive Control (Moxifloxacin)

NCT03606057
View directory record Official record
Conditions
Healthy
Interventions
JNJ-64565111, Moxifloxacin, JNJ-64565111-matching Placebo, Moxifloxacin-matching Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
188 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Mar 3, 2020 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Investigate the Effect of Balovaptan on the QTC Interval in Healthy Subjects

NCT03808298
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Balovaptan therapeutic dose Treatment A, Balovaptan supra-therapeutic dose Treatment B, Active control [moxifloxacin] on Day 2 Treatment C, Active control [Moxifloxacin] on Day 15 Treatment D, Placebo for Balovaptan Treatment C, Placebo for Balovaptan Treatment D, Placebo for Moxifloxacin Treatment A, Placebo for Moxifloxacin Treatment B, Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment C, Placebo for Moxifloxacin Treatment D, Moxifloxacin Treatment D
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 60 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 24, 2020 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

NCT04019652
View directory record Official record
Conditions
Hypertension, Mineralocorticoid Receptor Antagonist
Interventions
CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years to 45 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2019 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of the Cardiac Effects of ALXN1840 in Healthy Adults

NCT04560816
View directory record Official record
Conditions
Healthy
Interventions
ALXN1840, Placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Aug 14, 2023 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers

NCT02479308
View directory record Official record
Conditions
Healthy
Interventions
Moxifloxacin, ALKS 5461, Placebo
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
129 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 23, 2015 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 QT Study in Healthy Male Subjects

NCT01986894
View directory record Official record
Conditions
Clinical Pharmacology, Healthy Volunteer Study
Interventions
Placebo, Pomalidomide, Moxifloxacin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 12, 2019 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants

NCT06215521
View directory record Official record
Conditions
Healthy
Interventions
Pirtobrutinib, Placebo, Moxifloxacin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 55 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
2
States / cities
Dallas, Texas • Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Cardiac Safety of a Single Dose of AL-335 Administered on a Background of Simeprevir and Odalasvir and of Repeated Doses of Odalasvir Administered Alone in Healthy Participants

NCT03155893
View directory record Official record
Conditions
Healthy
Interventions
ODV Placebo (Matching 25 mg ODV), ODV Placebo (Matching 200 mg ODV), ODV Placebo (Matching 125 mg ODV), ODV Placebo (Matching 100 mg ODV), SMV Placebo (Matching 150 mg SMV), AL-335 Placebo (matching 1200 mg AL-335), Moxifloxacin Placebo (matching 400 mg moxifloxacin), ODV 25 mg, ODV 200 mg, ODV 125 mg, ODV 100 mg, SMV 150 mg, AL-335 1200 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 14, 2017 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Single Oral Dose Dapagliflozin QT Study

NCT00688493
View directory record Official record
Conditions
Healthy
Interventions
Dapagliflozin, Moxifloxacin, Placebo to match moxifloxacin and dapagliflozin
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years · Male only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 21, 2012 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect of Gabapentin on Cardiac Repolarization in Healthy Volunteers

NCT01516372
View directory record Official record
Conditions
Restless Legs Syndrome
Interventions
GEn 1200mg, Gen 6000 mg, GEn Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2021 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study To Evaluate The Effect Of PF-04447943 On Qtc Interval In Healthy Adult Subjects

NCT02785770
View directory record Official record
Conditions
Healthy
Interventions
PF-04447943, Placebo, Moxifloxacin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Dec 28, 2018 · Synced Oct 5, 2026, 7:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Cardiac Effects of Danicopan in Healthy Adults

NCT05016206
View directory record Official record
Conditions
Healthy
Interventions
Danicopan, Moxifloxacin-matching Placebo, Danicopan-matching placebo, Moxifloxacin
Drug
Lead sponsor
Alexion Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2021 · Synced Oct 5, 2026, 7:57 AM EDT